New stock news | Shenzhen Mindray Bio-Medical Electronics (300760.SZ) Hong Kong IPO prospectus invalidated.

The Hong Kong stock prospectus submitted by Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (referred to as: Shenzhen Mindray Bio-Medical Electronics, 300760.SZ) on November 10, 2025, expired after 6 months on May 10, 2026. Huatai International and Morgan Stanley were its joint sponsors when submitting the prospectus. According to the prospectus, Shenzhen Mindray Bio-Medical Electronics (300760.SZ) is a globally leading, innovation-driven world-class medical device company and a leader in medical digitalization. According to Frost & Sullivan data, in the Chinese medical device industry, the company's market value exceeded the sum of the top domestic companies (second to fifth place) in 2024, and its industrial revenue was more than double that of the second-ranking company. The company is currently ranked 23rd among the top global medical device companies and its ranking continues to rise. It is the only Chinese company listed among the top 30 medical device companies globally and one of the fastest companies to achieve this ranking since its establishment. For the years 2022 to 2024 and the six months ending June 30, 2025, the company's revenues were approximately RMB 30.366 billion, RMB 34.932 billion, RMB 36.726 billion, and RMB 16.743 billion respectively.